Latest filings (excl ownership)
8-K
Changes in Registrant's Certifying Accountant
6 May 24
8-K
Amendments to Articles of Incorporation or Bylaws
23 Apr 24
8-K
Sales Grew at an Average Rate of 14% Per Quarter During the Year
1 Apr 24
10-K
2023 FY
Annual report
28 Mar 24
DEF 14C
Information statement
15 Mar 24
8-K
Entry into a Material Definitive Agreement
6 Mar 24
PRE 14C
Preliminary information
5 Mar 24
DEF 14C
Information statement
4 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
1 Mar 24
PRE 14C
Preliminary information
21 Feb 24
8-K
Submission of Matters to a Vote of Security Holders
16 Feb 24
8-K
Sunshine Biopharma, Inc. Announces Pricing of $10.0 Million Underwritten Public Offering
15 Feb 24
424B4
Prospectus supplement with pricing info
14 Feb 24
EFFECT
Notice of effectiveness
13 Feb 24
8-K
Entry into a Material Definitive Agreement
12 Feb 24
S-1/A
IPO registration (amended)
9 Feb 24
CORRESP
Correspondence with SEC
9 Feb 24
CORRESP
Correspondence with SEC
9 Feb 24
UPLOAD
Letter from SEC
6 Feb 24
S-1
IPO registration
1 Feb 24
8-K
Departure of Directors or Certain Officers
30 Jan 24
S-8
Registration of securities for employees
8 Jan 24
8-K
Submission of Matters to a Vote of Security Holders
7 Dec 23
8-K
Revenues Up Significantly Over Last Year Due to a Key Acquisition
13 Nov 23
10-Q
2023 Q3
Quarterly report
13 Nov 23
8-K
Termination of a Material Definitive Agreement
2 Nov 23
8-K
Entry into a Material Definitive Agreement
20 Oct 23
DEFA14A
Additional proxy soliciting materials
19 Oct 23
DEF 14A
Definitive proxy
18 Oct 23
8-K
Submission of Matters to a Vote of Security Holders
13 Oct 23
8-K
Sunshine Biopharma Receives 180-DAY Extension to Achieve Nasdaq Minimum Bid Compliance
21 Sep 23
DEF 14A
Definitive proxy
5 Sep 23
UPLOAD
Letter from SEC
29 Aug 23
PRE 14A
Preliminary proxy
25 Aug 23
8-K
Results of Operations and Financial Condition
11 Aug 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
CORRESP
Correspondence with SEC
8 Aug 23
UPLOAD
Letter from SEC
25 Jul 23
EFFECT
Notice of effectiveness
6 Jun 23
424B3
Prospectus supplement
5 Jun 23
Latest ownership filings
4
Steve N. Slilaty
5 Mar 24
SC 13G
L1 Capital Global Opportunities Master Fund, Ltd.
23 Feb 24
SC 13G
Altium Capital Management LP
21 Feb 24
SC 13G
ARMISTICE CAPITAL, LLC
14 Feb 24
4
Steve N. Slilaty
12 Feb 24
3
Marc Beaudoin
9 Feb 24
4
Camille Sebaaly
2 Dec 22
SC 13G
Chamoun Malek
2 Nov 22
3
Malek Chamoun
26 Oct 22
4
Camille Sebaaly
6 Jun 22
4
Steve N. Slilaty
22 Feb 22
3
DAVID NATAN
18 Feb 22
3
Andrew Mark Keller
18 Feb 22
3
Rabi Kiderchah
16 Dec 21
3
James Daniel Kish
14 Dec 21
3
ANDREW I TELSEY
9 Dec 21
SC 13G
Beathard Robert King 3rd
29 Jul 21
4
ABDERRAZZAK MERZOUKI
16 Feb 21
4
Steve N. Slilaty
16 Feb 21
4
Camille Sebaaly
16 Feb 21
4
Camille Sebaaly
15 Jul 20
4
ABDERRAZZAK MERZOUKI
13 Jul 20
4
Steve N. Slilaty
10 Jul 20
4
Steve N. Slilaty
25 Jun 20
4
ABDERRAZZAK MERZOUKI
7 Oct 19
4/A
ABDERRAZZAK MERZOUKI
7 Oct 19
4/A
ABDERRAZZAK MERZOUKI
7 Oct 19
4/A
ABDERRAZZAK MERZOUKI
4 Oct 19
4/A
ABDERRAZZAK MERZOUKI
4 Oct 19
4/A
ABDERRAZZAK MERZOUKI
4 Oct 19
3/A
ABDERRAZZAK MERZOUKI
4 Oct 19
4
Camille Sebaaly
23 Sep 19
4
Steve N. Slilaty
23 Sep 19
4
Camille Sebaaly
14 Sep 18
4
ABDERRAZZAK MERZOUKI
14 Sep 18
4
Steve N. Slilaty
14 Sep 18
4
ABDERRAZZAK MERZOUKI
28 Jun 18
4
Camille Sebaaly
28 Jun 18
4
Steve N. Slilaty
28 Jun 18
4
Steve N. Slilaty
8 Sep 17